Novartis Ag

Elanco Tiergesundheit Ag

Rita Ramos

Michael Patrick Dillon

Lei Li

Liladhar Murlidhar Waykole

Heinrich Rueeger

Philipp Holzer

Nikolaus Johannes Stiefl

Lv Liao

Thomas Ullrich

Sven Weiler

Rene Lattmann

Xiaoyang Wang

Luca Arista

Tingying Zhu

Peggy Usselmann

Jialiang Li

Maurice Van Eis

Nigel Graham Cooke

Mathias Frederiksen

Sangamesh Badiger

Rainer Martin Lueoend

Murali Chebrolu

Dimitrios Lizos

Kai Cui

Yizong Zhou

Yubo Zhang

Sreehari Babu

Jianwei Bian

Karen Kammertoens

Andreas Kordikowski

Ulf Neumann

Nicole Bieri

Philipp Lustenberger

Vijay Sethuraman

Bin Li

Sisi Zhang

Konstanze Hurth

Rainer Machauer

Michael Schaefer

Henrik Moebitz

Marina Tintelnot-blomley

Siem Jacob Veenstra

Markus Voegtle

Hui Liu

Xin Xiong

The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Aminopyridine derivatives and their use as selective ALK-2 inhibitors

This application relates to various crystalline forms of (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water ('hydrates'). These materials are useful in the treatment of various autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis and psoriasis.

Crystalline forms of a TLR7/TLR8 inhibitor

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. 

The present invention relates to substituted indole derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Substituted indole derivatives

The invention relates to 5-cyano-3-methyl-pyridine-2-carboxylic acid [3-((3R,6R)-5-amino-3,6-dimethyl-6-trifluoromethyl-3,6-dihydro-2H-[1,4]oxazin-3-yl)-4-fluoro-phenyl]-amide in crystalline form, to its preparation, its medical use and to medicaments comprising said compound in crystalline form.

Crystalline oxazine derivative

Growing community of inventors

Allschwil, Switzerland

Rita Ramos